Anavex Life Sciences Corp.

NASDAQ:AVXL

Biotechnology

Healthcare
$0.72 -1.67%

-$0.04 today

Market cap
$66.69M
Beta
1.12
P/E (TTM)
-5.9
EPS (TTM)
-$0.45
52W Low $2.41High $13.99

Volume 1.06M

Average 1.39M

AVXL Net Receivables

Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.

Anavex Life Sciences Corp.NASDAQ: AVXL

Net Receivables · Q1 FY2026 · quarter ended Dec 2025

Net receivables falls 67.0% from a year ago

Net receivables stood at $844K at the end of Q1 FY2026, down 67.0% from a year earlier and up 4.3% from the prior quarter. Over 3 fiscal years it compounded at -36.7% a year.

Context

  • Net receivables amounted to 0.6% of total assets at the end of Q1 FY2026, down 1.4 pp from a year earlier.
  • Net receivables increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether net receivables keeps falling in the next quarterly balance sheet after a -67.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterDec 2025
$844K+4.3% QoQ
Last fiscal yearSep 2025
$809K-67.0% YoY
Year agoDec 2024
$2.56M-67.0% since
Net Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-67.0%——
1 year-67.0%——
3-year CAGR-36.7%——
5-year CAGR——
10-year CAGR——

Net Receivables history

USD · from the balance sheet

Latest · FY2025
809K USD
Year-over-year change
-67.0%
4-year CAGR
-45.5%

Net Receivables vs competitors

How AVXL compares with its peers on the latest reported figures

  • Peers report in different currencies, so net receivables is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -67.0% is the 7th highest of 10, against a peer median of -42.9%.
  • Net receivables amounts to 0.6% of total assets for AVXL, versus a peer median of 1.0%.
AVXL Competitors
Net Receivables for AVXL and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
MGTXMeiraGTx Holdings plcMar 2026$17.96M USD+243.7%-14.3%7.3%
RGNXREGENXBIO Inc.Mar 2026$10.94M USD-42.9%-3.3%3.2%
VALNValneva SEMar 2026€10.14M EUR-69.7%+5.2%2.7%
ARVNArvinas, Inc.Mar 2026$6.4M USD-23.8%-7.2%1.0%
MLTXMoonLake ImmunotherapeuticsMar 2026$5.76M USD+92.9%+182.0%1.4%
MBXMBX Biosciences, Inc. Common StockSep 2026$3.23M USD+108.7%+146.2%0.6%
AVXLAnavex Life Sciences Corp.Dec 2025$844K USD-67.0%-36.7%0.6%
CTMXCytomX Therapeutics, Inc.Mar 2026$646K USD-67.0%-61.8%0.2%
ERASErasca, Inc.Sep 2026$0 USD-100.0%—0.0%
ABSIAbsci CorporationMar 2026$0 USD-100.0%—0.0%
Peer median (excluding AVXL) —-42.9%-3.3%1.0%

Competitors are the stored peer set for AVXL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Sep 2021
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Cash & Equivalents152.11M149.16M151.02M132.19M102.58M
Short-term Investments00000
Net Receivables9.14M3.19M2.71M2.45M809K
Inventory16.37K0000
Other Current Assets(16.37K)162653K931K429K
Total Current Assets161.62M152.7M154.39M135.57M103.82M
Property, Plant & Equipment (Net)00000
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets16.37K3.55B3.36M00
Total Non-current Assets16.37K3.55B3.36M00
Total Assets161.62M152.7M154.39M135.57M103.82M
Account Payables4.74M3.82M4.32M9.63M4.25M
Short-term Debt00000
Tax Payables00000
Deferred Revenue443.83K443.83K917K842K805K
Other Current Liabilities0(47)1.36M1.53M1.56M
Total Current Liabilities10.8M10.21M12.53M15.3M8.95M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities00000
Total Liabilities10.8M10.21M12.53M15.3M8.95M
Common Stock75.92K77.94K82K85K87K
Retained Earnings(197.59M)(245.56M)(293.07M)(336.07M)(382.45M)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest00000
Total Equity150.82M142.49M141.85M120.26M94.87M
Total Debt00000
Net Debt(152.11M)(149.16M)(151.02M)(132.19M)(102.58M)

Anavex Life Sciences Corp.

NASDAQ:AVXL

Intrinsic Alpha fair value

Locked

Current Price

$0.72

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.